Alemtuzumab in relapsing-remitting multiple sclerosisWe are no longer recruiting for a trial of alemtuzumab and palifermin, called the“CAMTHY” trial. For more details, see here.Trial of anti-IL7 R in multiple sclerosis stoppedThe genetic studies in multiple sclerosis found that variations in the genecontrolloing the “interleukin 7 receptor” give a high or low risk of developingmultiple sclerosis. We were working in collaboration with GSK to test an antibodyagainst this receptor as a treatment for multiple sclerosis. Very sadly, this trial hadto be stopped - before anyone with MS had received the drug - because some of theoriginal data produced by GSK employees turned out to be fradulent.Preventing progressive multiple sclerosisWe are committed to research on people with multiple sclerosis.We are very keen tostart a trial of a new drug, called bexarotene, following the exciting experimentalwork of Prof Robin Franklin in Cambridge. This drug has the potential to promoteremyelination. We will post details of recruitment here when we can. This is nearlyready to go.